Life360, Inc. Common Stock (LIF) 8-K Update on Founder loans

Exhibit 99.2

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Life360, Inc.

ARBN: 629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher (Chris) Hulls
Date of last notice	15 June 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest	—
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	28 June 2023 (PST) (being 29 June 2023 AEST)
No. of securities held prior to change	•   5,059,656 CHESS Depositary Interests (CDIs)
	•   1,263,095 Shares of Common Stock (Shares)(equivalent to 3,789,285 CDIs)
	•   2,090,348 Options over Shares (Options)
	•   68,023 Restricted Stock Units (RSUs)
	•   89,880 CDIs held by ICCA Labs, LLC1
Class	CDIs
Number acquired	—

¹  Chris Hulls is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of CDIs attributable to Chris Hulls by reason of his membership interest in ICCA Labs, LLC is 89,880.

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Number disposed	1,711,661 CDIs (equivalent to 570,554 Shares).
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	CDIs were transferred in payment of the principal, accrued interest and expenses on a A$10.5 million loan facility2 at a price per CDI of A$7.31, the VWAP on 28 June 2023.
No. of securities held after change	•   3,347,995 CDIs (equivalent to 1,115,999 Shares)
	•   1,263,095 Shares (equivalent to 3,789,285 CDIs)
	•   2,090,348 Options
	•   68,023 RSUs
	•   89,880 CDIs held by ICCA Labs, LLC
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	CDIs were transferred in payment of a loan facility

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change	N/A

² Details of the loan facility were included in an Appendix 3Y lodged with the ASX on 29 June 2021.

+ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3_–⁺ Closed period

Were the interests in the securities or contracts detailed above traded duringa+ closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3